Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology
Portfolio Pulse from
Medtronic has received CE Mark approval for its BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, marking a significant advancement in personalized care for Parkinson's patients. This approval introduces the first closed-loop DBS system in the EU and UK.
January 13, 2025 | 7:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic has achieved CE Mark approval for its BrainSense™ Adaptive DBS and Electrode Identifier, enhancing its position in the healthcare technology market with a unique closed-loop system for Parkinson's treatment.
The CE Mark approval allows Medtronic to market its innovative BrainSense™ Adaptive DBS in the EU and UK, potentially increasing its market share and revenue in the region. The unique closed-loop system offers a competitive advantage, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100